|Bid||15.17 x 1100|
|Ask||19.68 x 3200|
|Day's Range||16.45 - 17.05|
|52 Week Range||13.24 - 21.48|
|Beta (3Y Monthly)||1.74|
|PE Ratio (TTM)||56.05|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.11|
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Helen Torley has been the CEO ofRead More...
Halozyme Therapeutics Inc NASDAQ/NGS:HALOView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HALO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HALO totaled $2.55 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
BREDA, the Netherlands and GHENT, Belgium and SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients. Under the terms of the agreement, argenx will pay an upfront payment of $30 million to Halozyme, $10 million per target for future target nominations and potential future payments of up to $160 million per selected target subject to achievement of specified development, regulatory and sales-based milestones.
Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF) is pleased to provide an operational update given the recent developments at the Company in the past few months and announces the closing of a promissory note financing. Halo's CEO, Kiran Sidhu, stated: “As we start the new year off, I would like to provide our investors with an update on Halo as the end of 2018 was an incredibly busy time for the Company. In 2019, we expect to see the results of all that work come to fruition as the Company has transformed from a single state operator to a multi-state operator with California quickly become the driving force of the business.
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...
- Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation - Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with ...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
In the first nine months of 2018, Vanda Pharmaceuticals’ (VNDA) net revenues grew ~16% YoY to reach $140.1 million from $120.8 million. In the third quarter, the company’s net revenues amounted to $49.1 million, reflecting ~19% YoY growth. Wall Street analysts estimate that Vanda Pharmaceuticals will generate revenues of $191.7 million in fiscal 2018.
On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.
Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.
NEW YORK, Dec. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SAN DIEGO , Dec. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 37th Annual ...
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") ...
Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. (“Halozyme” or the “Company”) (NASDAQ: HALO). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.